IL-15: from discovery to FDA approval

Abstract

In April 2024, the FDA approved the interleukin (IL)−15 superagonist, N-803 (Anktiva, nogapendekin alfa inbakicept-pmln), for the treatment of bladder cancer [1]. This is the first cytokine in over 30 years to receive FDA approval for the treatment of cancer, and the culmination of years of preclinical and clinical studies involving both academic- and industry- driven research.

To understand the steps leading to this landmark approval, it is helpful to review some key historical events (Fig. 1). Notably, the first cytokines FDA approved for the treatment of cancer were interferon (type 1) (1986, hairy cell leukemia) and IL-2 (1992, renal cell carcinoma) [2]. Within a few years of their initial approvals, both cytokines would also receive other FDA approvals including for the treatment of metastatic melanoma. While both cytokines have broad immune stimulatory activities, IL-2 is unique in that it is also a powerful lymphocyte growth factor [3,4,5,6]. These qualities led to the evaluation and use of IL-2 with many other experimental immunotherapies including adoptive cell therapy. Notably, the adoptive transfer of tumor infiltrating lymphocytes (TIL) in combination with IL-2 first showed efficacy in human patients in the late 1980s [7]. After decades of work, in February 2024, TIL (lifileucel) in combination with IL-2 received FDA approval for the treatment of melanoma [8], which is the first approved adoptive cell therapy using lymphocytes for the treatment of a solid tumor.

Fig. 1

Timeline of key events related to the discovery and development of IL-15 and BCG as therapeutics

Full size image

Despite its established efficacy, IL-2 has a short half-life, and at approved doses, IL-2 can induce life threatening toxicities [9]. This side effect profile likely severely curtailed subsequent clinical development. Thus, high dose IL-2 as a monotherapy was FDA approved for renal cell carcinoma and metastatic melanoma, clinical development for other indications halted despite evidence of efficacy in other cancers [10]. Thus began the effort to develop alternatives with a similar mechanism of action.

The discovery of IL-15 in 1994 was the first step in the development of a promising alternative to IL-2 [4,5,6, 11,12,13]. Like IL-2, IL-15 is a powerful lymphocyte growth factor for CD8⁺ T cells and NK cells. Both IL-2 and IL-15 induce similar intracellular signaling through the shared IL-2 receptor (R) βγ subunits. However, while the private IL-2Rα (CD25) subunit improves responsiveness to limiting amounts of IL-2, IL-15 signals independently of IL-2Rα. Because IL-2Rα is expressed at high and constitutive levels on immune suppressive T regulatory cells, an advantage of IL-15 is that it does not expand T regulatory cells. By itself, IL-15 can induce anti-tumor activity in preclinical models [4, 5, 13]. Interestingly, IL-15 can be induced by type I interferon signaling [14, 15], which suggests a mechanism for type 1 interferon-mediated anti-tumor efficacy. Further differentiating IL-15 from IL-2 is the private IL-15Rα subunit. While thought to allow for high affinity cytokine binding, the description of IL-15Rα as a receptor is somewhat of a misnomer as IL-15Rα can transpresent IL-15 either on the cell surface or in soluble format [4, 16]. Building off this knowledge, we and others found that pre-association of soluble IL-15Rα subunit with IL-15 (with or without an Fc) could dramatically improve biological activity and half-life of IL-15 in vitro and in vivo, and these IL-15/IL-15Rα complexes had potent anti-tumor activity [17,18,19,20,21]. Based on this concept (Fig. 2), several companies have developed clinical grade reagents including N-803 (Anktiva), NIZ985, SOT101 (Nanrilkefusp alfa), and XmAb24306 (Efbalropendekin alfa) [22,23,24,25,26].

Fig. 2

Diagram of N-803 (IL-15/IL-15Rα cytokine complexes) including IL-15, IL-15Rα, and the Fc region from IgG1

Full size image

These IL-15 superagonists have now been evaluated in a wide range of clinical trials including patients with cancer and HIV-1 infection [23,24,25,26,27,28,29,30]. Similar to animal studies, human trials have shown IL-15/IL-15Rα complexes have improved half-life and cytokine-induced biological activity on human lymphocytes including CD8⁺ T cells and NK cells when compared to free IL-15 [25, 31, 32]. Importantly, at the doses used, this biological activity was obtained without the severe toxicities or need for in-hospital administration associated with high dose IL-2. For the agent in most advanced clinical testing, N-803, single agent activity was shown in patients with hematological malignancies who relapsed after allogeneic hematopoietic cell transplantation [25]. We and others have shown these agents can be administered safely in combination with other immunotherapy agents and with encouraging efficacy signals [26, 28, 30]. Thus, the combination of N-803 and anti-PD-1 mAb (nivolumab) could be given safely to NSCLC patients [30], and there is an ongoing phase III trial (NCT03520686). Taking advantage of the expansion and activation of Fc receptor-expressing immune cells such as NK cells that can mediate enhanced antibody-dependent cellular cytotoxicity, IL-15-based agents show the ability to enhance the efficacy of tumor-targeting antibodies [33]. Clinically, success with this concept has been demonstrated by combination of N-803 with rituximab (anti-CD20 mAb) [28]. Another appealing approach, not yet assessed clinically, is the use of systemic IL-15 agents instead of high dose IL-2 to support adoptively transferred T cells, such as TIL, administered after lymphodepletion. In addition to approaches using early generation IL-15 agents, it is notable that other approaches are in development including the use of fusion proteins combining IL-15 with targeting moieties (such as directing IL-15 to PD-1 expressing lymphocytes) and genetically encoded membrane-bound IL-15 [34, 35]. Expression of membrane-bound IL-15 on adoptively transferred lymphocytes may improve functional capacity and reduce the need for lymphodepleting chemotherapy [36].

The treatment of non-muscle invasive bladder cancer (NMIBC) involves the use of intravesical bacillus Calmette-Guerin (BCG) to avoid cystectomy [37, 38]. BCG was initially developed as a vaccine for tuberculosis, and since initial human testing in 1921, has been the most widely used vaccine worldwide [37,38,39]. Interest in using BCG for cancer therapy resulted from work by William Coley and others showing that bacterial agents may trigger anti-tumor immunity [40, 41], and BCG use in cancer patients was reported as early as 1936 [42]. Direct evidence in support of the use of BCG to induce anti-tumor immunity was supported by animal studies conducted by Lloyd Old, Burton Zbar, and others [43,44,45,46,47]. Evidence of BCG-mediated anti-tumor activity in humans was reported as early as 1965 in a mixed patient population [48]. Soon thereafter, evidence of BCG-mediated anti-tumor activity was reported in acute lymphoblastic leukemia [49], metastatic melanoma [50], and other cancers [37, 38, 51]. While our interpretation of the use of BCG as a cancer immunotherapy might be altered with today’s modern understanding of immunology, the practical clinical results of BCG therapy in bladder cancer would prove most impactful. Thus, in 1976 Alvaro Morales reported favorable responses in 9 patients with superficial bladder cancer treated as part of the first human trial using intravesical BCG [52]. This work was followed by randomized trials confirming efficacy [53,54,55,56], leading the FDA to approve BCG for NMIBC in 1990 [37].

While intravesical BCG can lead to durable responses in NMIBC, up to 40% of patients have disease recurrence at which time patients are thought to be unresponsive to additional BCG administration [54, 57, 58]. With the goal of improving BCG-mediated anti-tumor immunity, preclinical bladder cancer studies in rats demonstrated the combination of IL-15 and BCG delivery by intravesical instillation was safe and improved anti-tumor immunity [59,60,61]. The mechanism of action in these preclinical studies was not fully established, but responses were associated with expansion of NK cells and inflammatory cytokines. Given the encouraging preclinical studies, the combination of intravesical N-803 and BCG was evaluated in NMIBC patients, and in a phase I trial, encouraging safety, tolerability, and long-term outcomes were observed [62]. Intravesical N-803 given with BCG was then evaluated in a single-arm, multicenter trial of BCG-unresponsive, high-risk NMIBC patients with carcinoma in situ with or without papillary tumors [63] (NCT0302285, QUILT-3.032). In data reported by the FDA, 62% of the 77 patients enrolled had a complete response, with 58% of patients sustaining this complete response for 12 months. This response rate far exceeded guidance of 30% complete response at 1 year set by FDA experts and the International Bladder Cancer Group [64,65,66]. As a result, in April 2024 the FDA approved N-803 with BCG for this patient population [1], which represents the first FDA approval of any IL-15 based therapy.

While this FDA approval represents a promising step for patients, critical questions remain including the need for in-depth studies to establish the mechanism of action of the combination of N-803 and BCG. The latter will be helpful for the design of future therapies for bladder cancer patients. More broadly, this FDA approval is noteworthy as it represents the first of a new era of approvals for cytokines in the treatment of cancer. For IL-15 superagonists, future approvals might be for recombinant protein or genetically encoded constructs, however, it may also be for an IL-15-concept not yet envisioned.

No datasets were generated or analysed during the current study.

1. FDA. FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer. 2024

2. Waldmann TA. Cytokines in cancer immunotherapy. Cold Spring Harb Perspect Biol. 2018;10(12):a028472.

   Article CAS PubMed PubMed Central Google Scholar

3. Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014;192(12):5451–8 (PMC6293462).

   Article CAS PubMed Google Scholar

4. Wrangle JM, Patterson A, Johnson CB, Neitzke DJ, Mehrotra S, Denlinger CE, Paulos CM, Li Z, Cole DJ, Rubinstein MP. IL-2 and beyond in cancer immunotherapy. J Interferon Cytokine Res. 2018;38(2):45–68 (PMC5815463).

   Article CAS PubMed PubMed Central Google Scholar

5. Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol. 2006;6(8):595–601.

   Article CAS PubMed Google Scholar

6. Leonard WJ, Lin JX, O’Shea JJ. The gamma(c) family of cytokines: basic biology to therapeutic ramifications. Immunity. 2019;50(4):832–50.

   Article CAS PubMed Google Scholar

7. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319(25):1676–80.

   Article CAS PubMed Google Scholar

8. Julve M, Lythgoe MP, Larkin J, Furness AJS. Lifileucel: the first cellular therapy approved for solid tumours. Trends Cancer. 2024;10(6):475–7.

   Article CAS PubMed Google Scholar

9. Marabondo S, Kaufman HL. High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions. Expert Opin Drug Saf. 2017;16(12):1347–57.

   Article CAS PubMed Google Scholar

10. Tester WJ, Kim KM, Krigel RL, Bonomi PD, Glick JH, Asbury RF, Kirkwood JM, Blum RH, Schiller JH. A randomized phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer: an eastern cooperative oncology group study (PZ586). Lung Cancer. 1999;25(3):199–206.

    Article CAS PubMed Google Scholar

11. Grabstein KH, Eisenman J, Shanebeck K, Rauch C, Srinivasan S, Fung V, Beers C, Richardson J, Schoenborn MA, Ahdieh M, et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science. 1994;264(5161):965–8.

    Article CAS PubMed Google Scholar

12. Burton JD, Bamford RN, Peters C, Grant AJ, Kurys G, Goldman CK, Brennan J, Roessler E, Waldmann TA. A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci USA. 1994;91(11):4935–9 (PMC43904).

    Article CAS PubMed PubMed Central Google Scholar

13. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood. 2001;97(1):14–32.

    Article CAS PubMed Google Scholar

14. Zhang X, Sun S, Hwang I, Tough DF, Sprent J. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity. 1998;8(5):591–9.

    Article CAS PubMed Google Scholar

15. Lodolce JP, Burkett PR, Boone DL, Chien M, Ma A. T cell-independent interleukin 15Ralpha signals are required for bystander proliferation. J Exp Med. 2001;194(8):1187–94 (PMC2193508).

    Article CAS PubMed PubMed Central Google Scholar

16. Castillo EF, Schluns KS. Regulating the immune system via IL-15 transpresentation. Cytokine. 2012;59(3):479–90 (PMC3422378).

    Article CAS PubMed PubMed Central Google Scholar

17. Dubois S, Patel HJ, Zhang M, Waldmann TA, Muller JR. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action. J Immunol. 2008;180(4):2099–106.

    Article CAS PubMed Google Scholar

18. Bergamaschi C, Rosati M, Jalah R, Valentin A, Kulkarni V, Alicea C, Zhang GM, Patel V, Felber BK, Pavlakis GN. Intracellular interaction of interleukin-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity. J Biol Chem. 2008;283(7):4189–99.

    Article CAS PubMed Google Scholar

19. Stoklasek TA, Schluns KS, Lefrancois L. Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J Immunol. 2006;177(9):6072–80 (PMC2847275).

    Article CAS PubMed Google Scholar

20. Rubinstein MP, Kovar M, Purton JF, Cho JH, Boyman O, Surh CD, Sprent J. Converting IL-15 to a superagonist by binding to soluble IL-15Ralpha. Proc Natl Acad Sci U S A. 2006;103(24):9166–71 (PMC1482584).

    Article CAS PubMed PubMed Central Google Scholar

21. Mortier E, Quemener A, Vusio P, Lorenzen I, Boublik Y, Grotzinger J, Plet A, Jacques Y. Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins. J Biol Chem. 2006;281(3):1612–9.

    Article CAS PubMed Google Scholar

22. Han KP, Zhu X, Liu B, Jeng E, Kong L, Yovandich JL, Vyas VV, Marcus WD, Chavaillaz PA, Romero CA, Rhode PR, Wong HC. IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization. Cytokine. 2011;56(3):804–10 (PMC3221918).

    Article CAS PubMed PubMed Central Google Scholar

23. Lu D, Yadav R, Holder P, Chiang E, Sanjabi S, Poon V, Bernett M, Varma R, Liu K, Leung I, Bogaert L, Desjarlais J, Shivva V, Hosseini I, Ramanujan S. Complex PK-PD of an engineered IL-15/IL-15Ralpha-Fc fusion protein in cynomolgus monkeys: QSP modeling of lymphocyte dynamics. Eur J Pharm Sci. 2023;186:106450.

    Article CAS PubMed Google Scholar

24. Danek P, Simonova E, Podzimkova N, Bechard D, Sachse R, Kiemle-Kallee J, Moebius U, Spisek R, Adkins I, Steegmaier M, Jelinkova LP. 713 Nanrilkefusp alfa, a high-affinity IL-15Rβγ agonist, promotes an innate and adaptive anti-tumour inflammatory environment as single agent or combined with anti-PD-1 in patients with advanced cancers. J Immunother Cancer. 2023;11:A808–A808.

    Google Scholar

25. Romee R, Cooley S, Berrien-Elliott MM, Westervelt P, Verneris MR, Wagner JE, Weisdorf DJ, Blazar BR, Ustun C, DeFor TE, Vivek S, Peck L, DiPersio JF, Cashen AF, Kyllo R, Musiek A, Schaffer A, Anadkat MJ, Rosman I, Miller D, Egan JO, Jeng EK, Rock A, Wong HC, Fehniger TA, & Miller JS. First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood 2018;131(23): 2515–2527. PMC5992862 research support from Altor BioScience, a Nantworks company, but have no financial benefit from the outcome of this trial. J.O.E., E.K.J., A.R., and H.C.W. are employees of Altor BioScience and declare direct financial conflicts. To manage these conflicts, UMN and WUSM investigators led this trial, were sponsors of the IND, managed all the data in the study, and had final responsibility for the manuscript. The study protocol was an investigator-initiated clinical trial. UMN and WUSM investigators performed the clinical trial including data collection, analysis, and interpretation. Altor BioScience performed ALT-803 and cytokine measurements and immunogenicity testing on coded samples. The remaining correlative assays and all statistical analyses were performed by UMN and WUSM. The remaining authors declare no competing financial interests.

26. Leidner R, Conlon K, McNeel DG, Wang-Gillam A, Gupta S, Wesolowski R, Chaudhari M, Hassounah N, Lee JB, Ho Lee L, O'Keeffe JA, Lewis N, Pavlakis GN, Thompson JA. First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Ralpha, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors. J Immunother Cancer 2023;11(10)

27. Miller JS, Davis ZB, Helgeson E, Reilly C, Thorkelson A, Anderson J, Lima NS, Jorstad S, Hart GT, Lee JH, Safrit JT, Wong H, Cooley S, Gharu L, Chung H, Soon-Shiong P, Dobrowolski C, Fletcher CV, Karn J, Douek DC, Schacker TW. Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial. Nat Med. 2022;28(2):392–400.

    Article CAS PubMed Google Scholar

28. Foltz JA, Hess BT, Bachanova V, Bartlett NL, Berrien-Elliott MM, McClain E, Becker-Hapak M, Foster M, Schappe T, Kahl B, Mehta-Shah N, Cashen AF, Marin ND, McDaniels K, Moreno C, Mosior M, Gao F, Griffith OL, Griffith M, Wagner JA, Epperla N, Rock AD, Lee J, Petti AA, Soon-Shiong P, Fehniger TA. Phase I trial of N-803, an IL15 receptor agonist, with rituximab in patients with indolent non-hodgkin lymphoma. Clin Cancer Res. 2021;27(12):3339–50 (PMC8197753).

    Article CAS PubMed PubMed Central Google Scholar

29. Margolin K, Morishima C, Velcheti V, Miller JS, Lee SM, Silk AW, Holtan SG, Lacroix AM, Fling SP, Kaiser JC, Egan JO, Jones M, Rhode PR, Rock AD, Cheever MA, Wong HC, Ernstoff MS. Phase I trial of ALT-803, a novel recombinant IL15 complex, in patients with advanced solid tumors. Clin Cancer Res. 2018;24(22):5552–61.

    Article CAS PubMed PubMed Central Google Scholar

30. Wrangle JM, Velcheti V, Patel MR, Garrett-Mayer E, Hill EG, Ravenel JG, Miller JS, Farhad M, Anderton K, Lindsey K, Taffaro-Neskey M, Sherman C, Suriano S, Swiderska-Syn M, Sion A, Harris J, Edwards AR, Rytlewski JA, Sanders CM, Yusko EC, Robinson MD, Krieg C, Redmond WL, Egan JO, Rhode PR, Jeng EK, Rock AD, Wong HC, Rubinstein MP. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018;19(5):694–704 (PMC6089612).

    Article CAS PubMed PubMed Central Google Scholar

31. Rubinstein MP, Williams C, Mart C, Beall J, MacPherson L, Azar J, Swiderska-Syn M, Manca P, Gibney BC, Robinson MD, Krieg C, Hill EG, Taha SA, Rock AD, Lee JH, Soon-Shiong P, Wrangle J. Phase I trial characterizing the pharmacokinetic profile of N-803, a chimeric IL-15 superagonist. Healthy Volunt J Immunol. 2022;208(6):1362–70.

    Article CAS Google Scholar

32. Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC, Fleisher TA, Dubois SP, Perera LP, Stewart DM, Goldman CK, Bryant BR, Decker JM, Chen J, Worthy TA, Figg WD, Sr., Peer CJ, Sneller MC, Lane HC, Yovandich JL, Creekmore SP, Roederer M, & Waldmann TA. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol 2015;33(1):74–82. PMC4268254 online at www.jco.org. Author contributions are found at the end of this article

33. Zhang M, Wen B, Anton OM, Yao Z, Dubois S, Ju W, Sato N, DiLillo DJ, Bamford RN, Ravetch JV, Waldmann TA. IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages. Proc Natl Acad Sci USA. 2018;115(46):E10915–24 (PMC6243244).

    Article CAS PubMed PubMed Central Google Scholar

34. Hurton LV, Singh H, Najjar AM, Switzer KC, Mi T, Maiti S, Olivares S, Rabinovich B, Huls H, Forget MA, Datar V, Kebriaei P, Lee DA, Champlin RE, Cooper LJ. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc Natl Acad Sci U S A. 2016;113(48):E7788–97 (PMC5137758).

    Article CAS PubMed PubMed Central Google Scholar

35. Shen J, Zou Z, Guo J, Cai Y, Xue D, Liang Y, Wang W, Peng H, Fu YX. An engineered concealed IL-15-R elicits tumor-specific CD8+T cell responses through PD-1-cis delivery. J Exp Med 2022;219(12). PMC9521244 based fusion proteins" pending. No other disclosures were reported

36. Sanchez-Moreno I, Lasarte-Cia A, Martin-Otal C, Casares N, Navarro F, Gorraiz M, Sarrion P, Hervas-Stubbs S, Jordana L, Rodriguez-Madoz JR, San Miguel J, Prosper F, Lasarte JJ, Lozano T. Tethered IL15-IL15Ralpha augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in an immunocompetent lymphoma mouse model. J Immunother Cancer 2024;12(7). PMC11218034

37. Herr HW, Morales A. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol. 2008;179(1):53–6.

    Article PubMed Google Scholar

38. Hersh EM, Gutterman JU, Mavligit GM. BCG as adjuvant immunotherapy for neoplasia. Annu Rev Med. 1977;28:489–515.

    Article CAS PubMed Google Scholar

39. Luca S, Mihaescu T. History of BCG vaccine. Maedica (Bucur). 2013;8(1):53–8 (PMC3749764).

    PubMed Google Scholar

40. Kucerova P, Cervinkova M. Spontaneous regression of tumour and the role of microbial infection–possibilities for cancer treatment. Anticancer Drugs. 2016;27(4):269–77 (PMC4777220).

    Article CAS PubMed PubMed Central Google Scholar

41. Nauts HC, Swift WE, Coley BL. The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, M.D., reviewed in the light of modern research. Cancer Res. 1946;6:205–16.

    CAS PubMed Google Scholar

42. Holmgren I. Employment of B. C. G., especially in intravenous injection. Acta Med Scand. 1936;90(S78):350–61.

    Article Google Scholar

43. Old LJ, Clarke DA, Benacerraf B. Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse. Nature. 1959;184(Suppl 5):291–2.

    Article Google Scholar

44. Zbar B, Bernstein I, Tanaka T, Rapp HJ. Tumor immunity produced by the intradermal inoculation of living tumor cells and living Mycobacterium bovis (strain BCG). Science. 1970;170(3963):1217–8.

    Article CAS PubMed Google Scholar

45. Bast RC Jr, Zbar B, Borsos T, Rapp HJ. BCG and cancer (first of two parts). N Engl J Med. 1974;290(25):1413–20.

    Article PubMed Google Scholar

46. Lemonde P, Clode M. Effect of BCG infection on leukemia and polyoma in mice and hamsters. Proc Soc Exp Biol Med. 1962;111:739–42.

    Article CAS PubMed Google Scholar

47. Weiss DW, Bonhag RS, Deome KB. Protective activity of fractions of tubercle bacilli against isologous tumours in mice. Nature. 1961;190:889–91.

    Article CAS PubMed Google Scholar

48. Villasor RP. The clinical use of BCG vaccine in stimulating host resistance to cancer. J Philipp Med Assoc. 1965;41(9):619–32.

    CAS PubMed Google Scholar

49. Mathe G, Amiel JL, Schwarzenberg L, Schneider M, Cattan A, Schlumberger JR, Hayat M, De Vassal F. Active immunotherapy for acute lymphoblastic leukaemia. Lancet. 1969;1(7597):697–9.

    Article CAS PubMed Google Scholar

50. Morton D, Eilber FR, Malmgren RA, Wood WC. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 1970;68(1):158–163; discussion 163–154

51. Bast RC Jr, Zbar B, Borsos T, Rapp HJ. BCG and cancer. N Engl J Med. 1974;290(26):1458–69.

    Article PubMed Google Scholar

52. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180–3.

    Article CAS PubMed Google Scholar

53. Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol. 1980;124(1):38–40.

    Article CAS PubMed Google Scholar

54. Jiang S, Redelman-Sidi G. BCG in bladder cancer immunotherapy. Cancers (Basel) 2022;14(13). PMC9264881

55. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA Jr, Sullivan J, Sarosdy MF, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991;325(17):1205–9.

    Article CAS PubMed Google Scholar

56. Brosman SA. Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol. 1982;128(1):27–30.

    Article CAS PubMed Google Scholar

57. Sfakianos JP, Kim PH, Hakimi AA, Herr HW. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guerin. J Urol. 2014;191(2):341–5 (PMC4157345).

    Article PubMed Google Scholar

58. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49(3):466–465; discussion 475–467

59. Gomes-Giacoia E, Miyake M, Goodison S, Sriharan A, Zhang G, You L, Egan JO, Rhode PR, Parker AS, Chai KX, Wong HC, Rosser CJ. Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion. PLoS One 2014;9(6):e96705. PMC4045574 have declared that no competing interests exist. LY, JOE, PRR and HCW are employees of Altor BioScience Corp. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials

60. Furuya H, Chan OTM, Pagano I, Zhu C, Kim N, Peres R, Hokutan K, Alter S, Rhode P, Rosser CJ. Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model. J Transl Med. 2019;17(1):29 (PMC6337786).

    Article PubMed PubMed Central Google Scholar

61. Chen W, Liu N, Yuan Y, Zhu M, Hu X, Hu W, Wang S, Wang C, Huang B, Xing D. ALT-803 in the treatment of non-muscle-invasive bladder cancer: preclinical and clinical evidence and translational potential. Front Immunol. 2022;13:1040669 (PMC9684637).

    Article CAS PubMed PubMed Central Google Scholar

62. Rosser CJ, Tikhonenkov S, Nix JW, Chan OTM, Ianculescu I, Reddy S, Soon-Shiong P. Safety, tolerability, and long-term clinical outcomes of an IL-15 analogue (N-803) admixed with Bacillus Calmette-Guerin (BCG) for the treatment of bladder cancer. Oncoimmunology. 2021;10(1):1912885.

    Article PubMed PubMed Central Google Scholar

63. Chamie K, Chang SS, Kramolowsky E, Gonzalgo ML, Agarwal PK, Bassett JC, Bjurlin M, Cher ML, Clark W, Cowan BE, David R, Goldfischer E, Guru K, Jalkut MW, Kaffenberger SD, Kaminetsky J, Katz AE, Koo AS, Sexton WJ, Tikhonenkov SN, Trabulsi EJ, Trainer AF, Spilman P, Huang M, Bhar P, Taha SA, Sender L, Reddy S, Soon-Shiong P. IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer. NEJM Evid. 2023;2(1):EVIDo2200167.

    Article Google Scholar

64. Kamat AM, Sylvester RJ, Bohle A, Palou J, Lamm DL, Brausi M, Soloway M, Persad R, Buckley R, Colombel M, Witjes JA. Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group. J Clin Oncol 2016;34(16):1935–1944. PMC5321095 online at www.jco.org. Author contributions are found at the end of this article

65. Jarow JP, Lerner SP, Kluetz PG, Liu K, Sridhara R, Bajorin D, Chang S, Dinney CP, Groshen S, Morton RA, O’Donnell M, Quale DZ, Schoenberg M, Seigne J, Vikram B. Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a food and drug administration and American urological association public workshop. Urology. 2014;83(2):262–4.

    Article PubMed Google Scholar

66. Kamat AM, Colombel M, Sundi D, Lamm D, Boehle A, Brausi M, Buckley R, Persad R, Palou J, Soloway M, Witjes JA. BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG. Nat Rev Urol. 2017;14(4):244–55.

    Article PubMed Google Scholar

Download references

We are grateful to Anthony Baker, CMI, and Courtney Fleming, medical illustrators at The Ohio State University Medical Visuals, for creating the two figures.

The work from MPR and ZL is supported in part by NIH and the Pelotonia Institute for Immuno-Oncology. Support from NIH grants includes MPR (R01CA222817 and R01CA264525), JW (R01CA222817), and ZL (R01CA282501 and P01CA278732).

Authors and Affiliations

1. Pelotonia Institute for Immuno-Oncology, The Ohio State University, Columbus, OH, 43210, USA

   Zihai Li, Kai He & Mark P. Rubinstein

2. Division of Medical Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, 43210, USA

   Zihai Li, Kai He & Mark P. Rubinstein

3. Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, 43210, USA

   Zihai Li

4. Division of Hematology and Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC, 29425, USA

   John Wrangle

5. Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, 29425, USA

   John Wrangle

6. Immunology Division, Garvan Institute of Medical Research, Darlinghurst, 2010, Australia

   Jonathan Sprent

7. St. Vincent’s Clinical School, University of New South Wales, Sydney, 1466, Australia

   Jonathan Sprent

Authors

1. Zihai LiView author publications

   You can also search for this author in PubMed Google Scholar

2. John WrangleView author publications

   You can also search for this author in PubMed Google Scholar

3. Kai HeView author publications

   You can also search for this author in PubMed Google Scholar

4. Jonathan SprentView author publications

   You can also search for this author in PubMed Google Scholar

5. Mark P. RubinsteinView author publications

   You can also search for this author in PubMed Google Scholar

Contributions

Z.L. and M.P.R. conceived the idea and organized the writing. M.P.R. drafted the manuscript and received input from all authors. All authors reviewed and approved the final manuscript.

Corresponding author

Correspondence to Mark P. Rubinstein.

Consent for publication

Not applicable.

Competing interests

ZL serves as a member of the scientific advisory board for HanchorBio. The other authors declare no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

Cite this article

Li, Z., Wrangle, J., He, K. et al. IL-15: from discovery to FDA approval. J Hematol Oncol 18, 19 (2025). https://doi.org/10.1186/s13045-025-01664-8

Download citation

• Received: 02 September 2024

• Accepted: 13 January 2025

• Published: 18 February 2025

• DOI: https://doi.org/10.1186/s13045-025-01664-8

Share this article

Anyone you share the following link with will be able to read this content:

Get shareable link

Sorry, a shareable link is not currently available for this article.

Copy to clipboard

Provided by the Springer Nature SharedIt content-sharing initiative